Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNA5 | P22460 | 2/20 | 0.35 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.34 |
| ▸ | PFKFB3 | Q16875 | 1/20 | 0.34 |
| ▸ | OXTR | P30559 | 1/20 | 0.32 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | USP2 | O75604 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.31 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.30 |
| ▸ | CRHR1 | P34998 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4459564 | 0.95 | CYP19A1 (0.36) | KCNA5CYP19A1PFKFB3OXTRMEN1 | |
| SCHEMBL4461880 | 0.87 | KCNA5 (0.35) | KCNA5CYP19A1PFKFB3OXTRPDE4D | |
| SCHEMBL4464269 | 0.87 | CYP19A1 (0.34) | KCNA5CYP19A1OXTRADORA2AROCK2 | |
| SCHEMBL4461625 | 0.86 | CYP19A1 (0.40) | KCNA5CYP19A1 | |
| SCHEMBL4461775 | 0.86 | KDM4E (0.33) | KCNA5CYP19A1PFKFB3OXTRKMT2A | |
| SCHEMBL4469601 | 0.85 | KCNA5 (0.42) | KCNA5CYP19A1PFKFB3PDE4DMEN1 | |
| SCHEMBL4462686 | 0.84 | CYP19A1 (0.40) | KCNA5CYP19A1PFKFB3OXTRPDE4D | |
| SCHEMBL4453034 | 0.84 | KCNA5 (0.33) | KCNA5CYP19A1 | |
| SCHEMBL5134383 | 0.83 | CYP3A4 (0.34) | KCNA5CYP19A1OXTRADORA2A | |
| SCHEMBL4452542 | 0.83 | TAAR1 (0.39) | KCNA5CYP19A1PDE4DADORA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090030043-A1 | Potassium Channel Inhibitors | MERCK SHARP & DOHME CORP. | 2009-01-29 | — | — | US | claimed |
| US-20090030043-A1 | Potassium Channel Inhibitors | MERCK SHARP & DOHME CORP. | 2009-01-29 | — | — | US | disclosed |
| WO-2007089679-A2 | POTASSIUM CHANNEL INHIBITORS | MERCK & CO., INC. (US) | 2007-08-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090030043-A1 | Potassium Channel Inhibitors | KCNJ2, KCNH2, KCNH3 | KCNA5 11/4885CYP19A1 4359/4885PFKFB3 2531/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.